Comparator 1

PreclinicalSmall molecule

AbbVie

Comparator 1 is one of 30 small molecule programs targeting Psoriasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisActive, not recruiting

PsoriasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Stelara

Johnson & Johnson

Preclinical

37 2

Cosentyx

Novartis

Preclinical

53 3

Taltz

Eli Lilly

Preclinical

20 4

Bimzelx

UCB

Preclinical

17 5

Humira

CCelltrion

Preclinical

42 6

Raptiva

Roche

Preclinical

10 7

Remicade

OOrganon and Co

Preclinical

20 8

Siliq

BBausch Health Americas, Inc.

Preclinical

14 9

Victoza

Novo Nordisk

Preclinical

2 10

Lovenox

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dapagliflozin2 trials

A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults

Not yet recruiting·AAJU Pharm Co., Ltd.·Phase 1·NCT07034781·50 enrolled

A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study

Not yet recruiting·AAJU Pharm Co., Ltd.·Phase 1·NCT07044765·32 enrolled

Psoriasis1 trial

Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

Withdrawn· AbbVie logo

AbbVie··NCT04799990

Alcohol Intoxication1 trial

Possible Effects of Energy Drink Ingestion on Perceived Alcohol Intoxication

Unknown status·MMedical University of Vienna·N/A·NCT01350089·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Comparator 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Comparator 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Comparator 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AbbVie

Comparator 1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dapagliflozin2 trials

Psoriasis1 trial

Alcohol Intoxication1 trial

References

Drug Info

Quick Facts

Related News